| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | -0.0086 | 0.8 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.0064 | 0.8 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.8 |